A Phase 3 interventional study of Sugammadex and Neostigmine in Burns, sponsored by University of Kansas Medical Center. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-09-28.
Sponsored by University of Kansas Medical Center · Phase 3, Interventional, and Treatment
The purpose of this study is to learn if there is a difference in recovery time when using sugammadex versus neostigmine. The researchers also hope to add further knowledge and data to the safety of using sugammadex in burn patients who are hypermetabolic.
719 studies on the registry are indexed under Burns; 145 are open to participants now.
This study's enrollment of 7 is below the median of 40 across 524 interventional studies indexed under Burns.
Browse Burns studies →University of Kansas Medical Center is the lead sponsor of 483 studies on the registry; 113 are open to participants now.
Of its 38 completed or terminated interventional studies of FDA-regulated products, 24 (63%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Muscle relaxant reversal will be attained with sugammadex 2 mg/kgm IV.
Drug: Sugammadex
Muscle relaxant reversal will be attained with neostigmine 50 mcg/kgm plus glycopyrrolate10 mcg/kgm IV.
Drug: Neostigmine · Drug: Glycopyrrolate
Sugammadex is indicated for the reversal of neuromuscular blockade.
Neostigmine is indicated for the reversal of neuromuscular blockade.
Glycopyrrolate is used in conjunction with neostigmine to prevent neostigmine's muscarinic effects.
Time to return to a 90% Train of Four (TOF) neuromuscular twitch
Time frame: Within 24 hours after surgery
Time to endotracheal extubation
Time frame: Within 24 hours after surgery
Time to discharge from the operating room
Time frame: Within 24 hours after surgery
This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Kansas Medical Center